3 buy-rated ASX 200 shares that analysts love

These ASX 200 shares are highly rated by analysts…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you're interested in adding some ASX 200 shares to your portfolio this week, then the three listed below could be worth considering.

These ASX 200 shares have all been named as buys recently. Here's what you need to know about them:

Three people in a corporate office pour over a tablet, ready to invest.

Image source: Getty Images

Cochlear Limited (ASX: COH)

The first ASX 200 share to look at is Cochlear. It is one of the world's leading hearing solutions companies with a portfolio of industry-leading cochlear implant devices.

Goldman Sachs is a fan of Cochlear. In response to its recent full year results, the broker reiterated its buy rating with an improved price target of $247.00. Goldman believes that Cochlear will grow its net profit by "a +10% CAGR from FY22-25E."

Goodman Group (ASX: GMG)

Another ASX 200 share that could be a top option for investors is Goodman Group. It is one of the world's leading integrated commercial and industrial property companies.

Goodman has been growing at a strong rate for years thanks to its expertly constructed portfolio that gives it exposure to key growth markets such as ecommerce and logistics.

The team at Citi is bullish on Goodman and expects its strong growth to continue. The broker recently commented: "We revise medium-term earnings higher and see upside to FY23 guidance of 90.3c (11% EPS growth) driven by (1) another strong year of development earnings growth, (2) continued rise in management and investment income driven by high asset values and recent development completions."

Citi has a buy rating and $23.50 price target on the company's shares.

ResMed Inc. (ASX: RMD)

A final ASX 200 share to look at is ResMed. It is another industry leader, this time in the sleep treatment market.

Like the others, the company has been growing at a strong rate for years and has been tipped to continue doing so for the foreseeable future.

Morgans is a fan of ResMed. It believes there is "a multi-year opportunity for RMD to growth at or above market and solidify its market leadership position." The broker has an add rating and $37.08 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Blue Chip Shares

Experts say these fantastic blue chip ASX 200 shares are buys

Are these blue chips in the buy zone? Experts say they are.

Read more »

A group of men in the office celebrate after winning big.
Blue Chip Shares

Brokers name 2 blue chip ASX 100 shares to buy

These ASX 100 shares tick a lot of boxes for analysts right now...

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Blue Chip Shares

Boost your portfolio with these blue chip ASX 200 shares in March: experts

Analysts believe that these blue chips could give your portfolio a big lift...

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Blue Chip Shares

Morgans names 2 ASX 50 shares to buy now

The ASX 50 is home to the 50 largest companies on the Australian share market...

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

These blue chip ASX 200 shares are post-results buys: experts

Results are in! These blue chip shares are in the buy zone right now...

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Blue Chip Shares

2 ASX 200 shares to buy post-results: Morgans

These ASX 200 shares have impressed analysts at Morgans during earnings season...

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Blue Chip Shares

Why experts say these ASX 200 blue chip shares are buys

Experts say that these ASX 200 blue chip shares from different side of the market are in the buy zone…

Read more »

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Blue Chip Shares

3 of the best ASX 200 shares to buy now: broker

These could be some of the best ASX 200 shares to buy in February according to one broker...

Read more »